REDAPT Anteverted Cemented Liner

K160923 · Smith & Nephew, Inc. · JDI · Nov 17, 2016 · Orthopedic

Device Facts

• Record ID: K160923
• Device Name: REDAPT Anteverted Cemented Liner
• Applicant: Smith & Nephew, Inc.
• Product Code: JDI · Orthopedic
• Decision Date: Nov 17, 2016
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3350
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Hip components are indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma or noninflammatory degenerative joint disease (NIDID) or any of its composite diagnoses of osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant. Hip components are also indicated for inflammatory degenerative joint disease including rheumatoid arthritis, atthritis secondary to a variety of diseases and anomalies, and congenital dysplasia; treatments of nonunion, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; endoprosthesis, femoral osteotomy, or Girdlestone resection: fracture-dislocation of the hip; and correction of deformity. The REDAPT Cemented Liner is intended for single use only and is to be implanted with bone cement.

Device Story

REDAPT Anteverted Cemented Liner is an acetabular component for hip arthroplasty; manufactured from highly cross-linked polyethylene. Device features integral polyethylene spheres creating 1.5 mm gap for consistent bone cement mantle. Implanted by orthopedic surgeons during primary or revision hip surgery; intended for single use. Device functions as bearing surface within acetabulum; provides stability and range of motion for hip joint. Mechanical performance validated via fatigue, push-out, lever-out, torque-to-failure, range of motion, and impingement testing. Benefits include restoration of hip function and mobility for patients with degenerative joint disease or trauma.

Clinical Evidence

Bench testing only. No clinical data provided. Mechanical testing included fatigue, push-out, lever-out, torque-to-failure, range of motion, and impingement. Bacterial endotoxin testing met ANSI/AAMI ST72 standards.

Technological Characteristics

Material: Highly cross-linked polyethylene (ASTM F648). Design: Acetabular liner with integral polyethylene spheres for 1.5 mm cement mantle gap. Energy source: None (passive implant). Connectivity: None. Sterilization: Not specified (compliance with sterility guidance noted).

Indications for Use

Indicated for individuals undergoing primary or revision hip surgery due to trauma, noninflammatory degenerative joint disease (osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fused hip, pelvic fracture, diastrophic variant), inflammatory degenerative joint disease (rheumatoid arthritis, congenital dysplasia), nonunion, femoral neck/trochanteric fractures, endoprosthesis, femoral osteotomy, Girdlestone resection, fracture-dislocation, or deformity correction.

Regulatory Classification

Identification

A hip joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and an acetabular resurfacing component made of ultra-high molecular weight polyethylene and is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

• REFLECTION Cross-Linked UHMWPE Acetabular Components (K002747)
• REDAPT Porous Shell and Cemented Liner (K150790)

Reference Devices

• REFLECTION XLPE Acetabular Liner (K022902)
• R3 XLPE Acetabular Liner (K113848)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an emblem featuring a stylized representation of three human profiles facing to the right, stacked on top of each other.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

November 17, 2016

Smith & Nephew, Inc. Ms. Kim Phan Regulatory Affairs Specialist Advanced Surgical Devices Division 7135 Goodlett Farms Parkway Cordova, Tennessee 38016

Re: K160923

Trade/Device Name: REDAPT Anteverted Cemented Liner Regulation Number: 21 CFR 888.3350 Regulation Name: Hip Joint Metal/Polymer Semi-Constrained Cemented Prosthesis Regulatory Class: Class II Product Code: JDI, KWZ, LZO Dated: October 27, 2016 Received: October 28, 2016

Dear Ms. Kim Phan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

{1}------------------------------------------------

the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K160923

Device Name REDAPT Anteverted Cemented Liner

#### Indications for Use (Describe)

· Hip components are indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma or noninflammatory degenerative joint disease (NIDID) or any of its composite diagnoses of osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant.

· Hip components are also indicated for inflammatory degenerative joint disease including rheumatoid arthritis, atthritis secondary to a variety of diseases and anomalies, and congenital dysplasia; treatments of nonunion, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; endoprosthesis, femoral osteotomy, or Girdlestone resection: fracture-dislocation of the hip; and correction of deformity.

The REDAPT Cemented Liner is intended for single use only and is to be implanted with bone cement.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------------------------------------------------------|-----------------------------------------------|
| <span style="text-decoration: underline;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## 510(k) Summary Smith & Nephew REDAPT Anteverted Cemented Liner

| Submitted by: | Smith & Nephew, Inc.<br>Advanced Surgical Devices Division<br>7135 Goodlett Farms Parkway<br>Cordova, Tennessee 38016 |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Date of Summary: | October 27th, 2016 |
| Contact Person | Kim Phan, Regulatory Affairs Specialist<br>T: [phone]<br>F: [phone] |
| Name of Device: | REDAPT Anteverted Cemented Liner |
| Common Name: | Hip Prosthesis, Acetabular Component |
| Device Classification Name and Reference: | 21 CFR 888.3350 – Prosthesis, Hip, Sem<br>Constrained, Metal/Polymer, Cemented |
| Device Class: | Class II |
| Panel Code: | Orthopaedics/87 |
| Product Code: | JDI, KWZ, LZO |

#### Device Description

The REDAPT Anteverted Cemented Liner is manufactured from highly cross-linked polyethylene (ASTM F648) via standard machining processes. The liners incorporate integral polyethylene spheres that create a 1.5 mm gap between the porous shell or natural acetabulum for a consistent bone cement mantle.

### Intended Use

The REDAPT Anteverted Cemented Liner are indicated for:

- Hip components are indicated for individuals undergoing primary and revision surgery ● where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma or noninflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses of osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant.
- . Hip components are also indicated for inflammatory degenerative joint disease including rheumatoid arthritis, arthritis secondary to a variety of diseases and anomalies, and congenital dysplasia; treatments of nonunion, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; endoprosthesis, femoral osteotomy, or Girdlestone resection; fracture-dislocation of the hip; and correction of deformity.

{4}------------------------------------------------

The REDAPT Cemented Liner is intended for single use only and is to be implanted with bone cement.

The above indications are substantially equivalent to the indications cleared for the REDAPT Cemented Liners cleared in K150790.

# Technological Characteristics

A review of the mechanical data indicates that the REDAPT Anteverted Liners are capable of withstanding expected in vivo loading without failure.

# Substantial Equivalence Information

The REDAPT Anteverted Cemented Liners are substantially equivalent to the following commercially available predicate devices by overall design, materials, or indications for use.

| Manufacturer | Description | Submission<br>Number | Clearance<br>Date | Predicate<br>Status |
|----------------|---------------------------------------------------------|----------------------|-------------------|---------------------------------|
| Smith & Nephew | REFLECTION Cross-Linked UHMWPE<br>Acetabular Components | K002747 | 12/15/2000 | Primary for<br>Cemented Liner |
| Smith & Nephew | REDAPT Porous Shell and<br>Cemented Liner | K150790 | 11/16/2015 | Primary for<br>Indications |
| Smith & Nephew | REFLECTION XLPE Acetabular Liner | K022902 | 10/2/2002 | Reference for<br>Cemented Liner |
| Smith & Nephew | R3 XLPE Acetabular Liner | K113848 | 4/24/2012 | Reference for<br>Cemented Liner |

The following tests were used as a basis for the determination of substantial equivalence:

- Fatigue ●
- Push out, Lever Out, and Torque-to-Failure ●
- Range of Motion ●
- Impingement

Wear performance of the cross-linked polyethylene liners are substantially equivalent to the REDAPT 0-Degree Liners in K150790 and the REFLECTION Liners in K002747.

Bacterial endotoxin testing was completed and met the acceptable endotoxin limits as stated in the FDA Guidance , "Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile," "Pyrogen and Endotoxins Testing: Questions and Answers," and ANSI/AAMI ST72.

# Conclusion

As previously noted, this 510(k) Premarket Notification is being submitted to request clearance for the REDAPT Anteverted Cemented Liner. Based on the similarities to the predicate component and a review of the mechanical testing performed, the devices are substantially equivalent to the commercially available predicate device listed above.